AI English summary of an SEC filing — figures as filed
STERIS STEThe company said revenues rose 7.3% to $1,328.9 million for the 3 months ended September 30, 2024, from $1,238.2 million a year earlier. It attributed the increase to organic growth, driven by volume in the Healthcare segment and pricing across all three segments.
Key points
AI summaryThe company said revenues rose 7.3% to $1,328.9 million for the 3 months ended September 30, 2024, from $1,238.2 million a year earlier. It attributed the increase to organic growth, driven by volume in the Healthcare segment and pricing across all three segments.
The company said its gross profit percentage for Q2 of fiscal 2025 was 43.6%, compared with 44.1% in the same period a year earlier. Unfavorable impacts from labor and overhead costs (160 basis points) were partially offset by pricing (130 basis points).
The company said it announced a targeted restructuring plan (the Restructuring Plan) in May 2024. It said it has recorded total pre-tax restructuring expense of $75.3 million since inception and expects to incur about $25.0 million in additional costs for the remainder of fiscal 2025.
The company said net cash provided by operating activities was $554.5 million for the first six months of fiscal 2025, compared with $427.2 million a year earlier, and free cash flow was $344.5 million, compared with $284.7 million a year earlier. It cited higher collections on accounts receivable and improved inventory management as factors.
Key figures
Quarter ended September 30, 2024
- Revenue
- $1.3B
- Operating income
- $220M
- Net income
- $150M
- EPS
- $1.51
- Gross profit
- $579M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Revenue for September 30, 2024 quarter $1,328.9 million
The company said revenues rose 7.3% to $1,328.9 million for the 3 months ended September 30, 2024, from $1,238.2 million a year earlier. It attributed the increase to organic growth, driven by volume in the Healthcare segment and pricing across all three segments.
Source · Based on the MD&A text of the filing
Gross profit percentage 43.6%
The company said its gross profit percentage for Q2 of fiscal 2025 was 43.6%, compared with 44.1% in the same period a year earlier. Unfavorable impacts from labor and overhead costs (160 basis points) were partially offset by pricing (130 basis points).
Source · Based on the MD&A text of the filing
Restructuring plan and cumulative costs $75.3 million
The company said it announced a targeted restructuring plan (the Restructuring Plan) in May 2024. It said it has recorded total pre-tax restructuring expense of $75.3 million since inception and expects to incur about $25.0 million in additional costs for the remainder of fiscal 2025.
Source · Based on the MD&A text of the filing
Operating cash flow for the 6 months $554.5 million
The company said net cash provided by operating activities was $554.5 million for the first six months of fiscal 2025, compared with $427.2 million a year earlier, and free cash flow was $344.5 million, compared with $284.7 million a year earlier. It cited higher collections on accounts receivable and improved inventory management as factors.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…